FDA says its safety review of abortion pill will continue into next year

The FDA has announced that its ongoing safety review of the abortion pill, mifepristone, will continue into next year. The review was initially launched in response to reports of rare but serious adverse events.

The FDA's extended timeline has been criticized by abortion opponents, who argue that the drug should be removed from the market.

However, abortion rights advocates have praised the FDA's decision, saying that it is crucial to ensure the safety of the medication.

The abortion pill has been a contentious issue in the United States, with ongoing legal battles over its availability.